title: Exacerbation of combined pulmonary fibrosis and emphysema syndrome during tocilizumab therapy for rheumatoid arthritis.
authors.affiliation: Service de rhumatologie, CHRU de Besançon, boulevard Fleming, 25030 Besançon, France. Electronic address: dwendling@chu-besancon.fr.
authors.forename: Daniel
authors.initials: D
authors.lastname: Wendling
authors.forename: Claire
authors.initials: C
authors.lastname: Vidon
authors.forename: Marie
authors.initials: M
authors.lastname: Godfrin-Valnet
authors.forename: Gilles
authors.initials: G
authors.lastname: Rival
authors.forename: Xavier
authors.initials: X
authors.lastname: Guillot
authors.forename: Clément
authors.initials: C
authors.lastname: Prati
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011656:Pulmonary Emphysema / Q000139:chemically induced* / Q000209:etiology; D011658:Pulmonary Fibrosis / Q000139:chemically induced* / Q000209:etiology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; C502936:tocilizumab
keywords: Interstitial lung disease; Pulmonary fibrosis; Rheumatoid arthritis; Tocilizumab